Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLFX7K)

• Drug Name: LCZ696 Drug Info
• Synonyms: DTXSID50239500

Indication

Disease Entry	ICD 11	Status	REF
Heart failure	BD10-BD13	Approved	[1]

• Cross-matching ID:
  PubChem CID: 71300864
  TTD Drug ID: DMLFX7K

Molecule-Related Drug Atlas

Drug(s) Targeting Neutral endopeptidase (MME)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Candoxatril	DMHJCGV	Hypertension	BA00-BA04	Phase 3	[2]
Gallopamil	DMXBR27	Asthma	CA23	Phase 2	[3]
SLV 306	DMCDON3	Acute decompensated heart failure	BD1Z	Phase 2	[4]
SLV-334	DMXCJKY	Brain injury	NA07.Z	Phase 2	[5]
VX-15	DMLWM4G	Huntington disease	8A01.10	Phase 2	[6]
Sampatrilat	DMXTOVE	Hypotension	BA20-BA21	Phase 2	[7]
SLV-338	DM7WKTM	Cardiovascular disease	BA00-BE2Z	Phase 1	[8]
GW-796406	DMQ46DN	Hypotension	BA20-BA21	Phase 1	[3]
Debio 0827	DMQIEFB	Chronic pain	MG30	Phase 1	[9]
CART-10 cells	DMQ4UJ6	Acute lymphoblastic leukaemia	2A85	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neutral endopeptidase (MME)	TT5TKPM	NEP_HUMAN	Modulator	[1]

References

• [1] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [2] Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13.
• [3] Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
• [4] The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
• [5] Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
• [8] Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15.
• [9] Clinical pipeline report, company report or official report of Debiopharm (2011).
• [10] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS